Department of Epidemiology and Biostatistics, Schulich School of Medicine, Western University, London, Ontario, Canada.
Mental Health and Addictions Research Group, Department of Health Sciences, University of York, York, United Kingdom.
JAMA Netw Open. 2024 Nov 4;7(11):e2444599. doi: 10.1001/jamanetworkopen.2024.44599.
Approximately 1 in 5 adults are diagnosed with depression in their lifetime. However, less than half receive help from a health professional, with the treatment gap being worse for individuals with socioeconomic disadvantage. Computer-assisted cognitive behavioral therapy (CCBT) is an effective and convenient strategy to treat depression; however, its cost-effectiveness in a sociodemographically diverse population remains unknown.
To evaluate the cost-effectiveness of clinician-supported CCBT compared with treatment as usual (TAU) in a primary care population with a substantial number of patients with low income, limited computer or internet access, and lack of college education.
DESIGN, SETTING, AND PARTICIPANTS: This economic evaluation was a randomized clinical trial-based cost-effectiveness analysis. The trial was conducted at the Departments of Family and Geriatric Medicine and Internal Medicine at the University of Louisville. Enrollment occurred from June 24, 2016, to May 13, 2019. Participants had mild to moderate depression and were followed up for 6 months after treatment completion. The last follow-up assessment was conducted on January 30, 2020. Statistical analysis was performed from August 2023 to August 2024.
CCBT intervention was provided for 12 weeks and included 9 modules ranging from behavioral activation and cognitive restructuring to relapse prevention strategies, supported by telephonic sessions with a clinician, in addition to TAU, which included standard clinical management in primary care.
The primary health outcome was quality-adjusted life years (QALYs), estimated using the Short-Form 12 questionnaire (SF-12). The secondary outcome was treatment response, defined as at least 50% improvement in the Patient Health Questionnaire. The intervention cost included sessions with mental health clinicians and the cost of the CCBT software, plus the cost of loaner computer and internet data plan for low-resource households. An incremental cost-effectiveness ratio (ICER) was computed, while adjusting for baseline scores, age, and sex. The cost-effectiveness acceptability curve presented the probability of CCBT being cost-effective for a range of willingness-to-pay values.
Among the 175 primary care patients included in this study, 148 (84.5%) were female; 48 (27.4%) were African American, 2 (1.2%) were American Indian or Alaska Native, 4 (2.5%) were Hispanic, 106 (60.5%) were White, and 15 (8.6%) were multiracial; and the mean (SD) age was 47.03 (13.15) years. CCBT was associated with better quality of life and higher chance of treatment response at the posttreatment and 6-month time points, compared with the TAU group. The ICER for CCBT was $37 295 (95% CI, $22 724-$66 546) per QALY, with a probability of 89.4% of being cost-effective at a willingness-to-pay threshold of $50 000/QALY. The ICER per case of treatment response was $3623 (95% CI, $2617-$5377).
In this trial-based economic evaluation, CCBT was found to be cost-effective, compared with TAU, in primary care patients with depression. As this study included individuals with low income and with limited internet access who are underrepresented in cost-effectiveness studies, it has important policy implications for addressing unmet needs in sociodemographically diverse populations.
大约有五分之一的成年人在其一生中被诊断出患有抑郁症。然而,只有不到一半的人会得到健康专业人员的帮助,而社会经济劣势的个体的治疗差距更大。计算机辅助认知行为疗法(CCBT)是一种有效且方便的治疗抑郁症的策略;然而,其在社会人口统计学多样化人群中的成本效益仍然未知。
评估在一个初级保健人群中,与常规治疗(TAU)相比,临床医生支持的 CCBT 的成本效益,该人群中有相当数量的患者收入较低、计算机或互联网访问受限,且缺乏大学教育。
设计、设置和参与者:这是一项基于随机临床试验的成本效益分析。该试验在路易斯维尔大学的家庭和老年医学系以及内科系进行。招募于 2016 年 6 月 24 日至 2019 年 5 月 13 日进行。参与者患有轻度至中度抑郁症,并在治疗结束后随访 6 个月。最后一次随访评估于 2020 年 1 月 30 日进行。统计分析于 2023 年 8 月至 2024 年 8 月进行。
CCBT 干预持续 12 周,包括 9 个模块,范围从行为激活和认知重构到复发预防策略,由电话会议与临床医生提供支持,此外还包括 TAU,包括初级保健中的标准临床管理。
主要健康结果是质量调整生命年(QALYs),使用短期 12 问卷(SF-12)进行估计。次要结果是治疗反应,定义为患者健康问卷至少改善 50%。干预成本包括心理健康临床医生的会议费用和 CCBT 软件的成本,加上低资源家庭的贷款计算机和互联网数据计划的成本。计算了增量成本效益比(ICER),同时调整了基线评分、年龄和性别。成本效益接受性曲线呈现了 CCBT 在一系列支付意愿值范围内具有成本效益的概率。
在这项研究中,纳入了 175 名初级保健患者,其中 148 名(84.5%)为女性;48 名(27.4%)为非裔美国人,2 名(1.2%)为美洲印第安人或阿拉斯加原住民,4 名(2.5%)为西班牙裔,106 名(60.5%)为白人,15 名(8.6%)为多种族;平均(SD)年龄为 47.03(13.15)岁。与 TAU 组相比,CCBT 治疗在治疗后和 6 个月时间点与更高的生活质量和更高的治疗反应几率相关。CCBT 的 ICER 为 37295 美元(95%CI,22724 美元至 66546 美元)/QALY,在支付意愿阈值为 50000 美元/QALY 时,有 89.4%的可能性具有成本效益。每例治疗反应的 ICER 为 3623 美元(95%CI,2617 美元至 5377 美元)。
在这项基于试验的经济评估中,与 TAU 相比,CCBT 在初级保健抑郁症患者中具有成本效益。由于这项研究包括收入较低和互联网访问受限的个体,他们在成本效益研究中代表性不足,因此对解决社会人口统计学多样化人群中未满足的需求具有重要的政策意义。